Fig. 2From: A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in SingaporeCost-effectiveness acceptability curve. BAT, best available therapy; QALY, quality-adjusted life year; SGD, Singapore dollarBack to article page